Dianthus Therapeutics Statistics Share Statistics Dianthus Therapeutics has 32.19M
shares outstanding. The number of shares has increased by 9.56%
in one year.
Shares Outstanding 32.19M Shares Change (YoY) 9.56% Shares Change (QoQ) 0.11% Owned by Institutions (%) 99.99% Shares Floating 23.48M Failed to Deliver (FTD) Shares 1 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 5.98M, so 18.59% of the outstanding
shares have been sold short.
Short Interest 5.98M Short % of Shares Out 18.59% Short % of Float 22.75% Short Ratio (days to cover) 18.05
Valuation Ratios The PE ratio is -8.55 and the forward
PE ratio is -6.76.
Dianthus Therapeutics's PEG ratio is
0.12.
PE Ratio -8.55 Forward PE -6.76 PS Ratio 116.48 Forward PS 330.6 PB Ratio 2.06 P/FCF Ratio -9.28 PEG Ratio 0.12
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Dianthus Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 15.22,
with a Debt / Equity ratio of 0.
Current Ratio 15.22 Quick Ratio 15.22 Debt / Equity 0 Debt / EBITDA -0.01 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $79.94K Profits Per Employee $-1.09M Employee Count 78 Asset Turnover 0.02 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -0.45% in the
last 52 weeks. The beta is 1.46, so Dianthus Therapeutics's
price volatility has been higher than the market average.
Beta 1.46 52-Week Price Change -0.45% 50-Day Moving Average 21.13 200-Day Moving Average 21.07 Relative Strength Index (RSI) 70.68 Average Volume (20 Days) 356,109
Income Statement In the last 12 months, Dianthus Therapeutics had revenue of 6.24M
and earned -84.97M
in profits. Earnings per share was -2.55.
Revenue 6.24M Gross Profit 6.24M Operating Income -101.86M Net Income -84.97M EBITDA -101.45M EBIT -101.86M Earnings Per Share (EPS) -2.55
Full Income Statement Balance Sheet The company has 22.79M in cash and 1.49M in
debt, giving a net cash position of 21.3M.
Cash & Cash Equivalents 22.79M Total Debt 1.49M Net Cash 21.3M Retained Earnings -174.39M Total Assets 326.08M Working Capital 243.51M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -78.18M
and capital expenditures -105K, giving a free cash flow of -78.28M.
Operating Cash Flow -78.18M Capital Expenditures -105K Free Cash Flow -78.28M FCF Per Share -2.35
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -1633.74% and -1362.77%.
Gross Margin 100% Operating Margin -1633.74% Pretax Margin -1362.77% Profit Margin -1362.77% EBITDA Margin -1627.14% EBIT Margin -1633.74% FCF Margin -1255.57%
Dividends & Yields DNTH does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for DNTH is $50,
which is 88.7% higher than the current price. The consensus rating is "Buy".
Price Target $50 Price Target Difference 88.7% Analyst Consensus Buy Analyst Count 8
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 12, 2023. It was a
backward
split with a ratio of 1:16.
Last Split Date Sep 12, 2023 Split Type backward Split Ratio 1:16
Scores Altman Z-Score 18.61 Piotroski F-Score 1
